BioProspect cops Euro setback

By Graeme O'Neill
Friday, 01 July, 2005

Brisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths.

Neudorff cited concerns about the estimated cost of manufacturing and registering a formulated Qcide product for Germany and Europe.

Only three months ago, BioProspect received a similar knockback from another potential partner, Sumitomo Australia. At the time, Bioprospect said the Neudorff trials were "progressing very well".

In the wake of thefailed deal, the company said it was continuing with other confidential evaluation agreements in Australia and the US for the consumer goods and animal markets.

Related News

Cannabis use may double risk of cardiovascular disease death

Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...

Space conditions can lead to periodontitis, scientists say

Living in zero gravity can lead to periodontitis — a serious condition where the gums...

Personalised brain stimulation helps treat those with depression

By tailoring transcranial magnetic stimulation to each person's unique brain structure,...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd